Innoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI); ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI); and TRELEGY ELLIPTA (the combination FF/UMEC/VI). It has Long-Acting Beta2 Agonist collaboration agreement with GSK to develop and commercialize once-daily LABA products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was founded in 1996 and is headquartered in Brisbane, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:INVA
CUSIP88338T10
Phone650-238-9600
Debt
Debt-to-Equity Ratio-2.28
Current Ratio27.89
Quick Ratio27.89
Price-To-Earnings
Trailing P/E Ratio12.30
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$217.22 million
Price / Sales6.61
Cash Flow$1.4238 per share
Price / Cash9.91
Book Value($2.38) per share
Price / Book-5.93
Profitability
EPS (Most Recent Fiscal Year)$1.17
Net Income$134.14 million
Net Margins64.11%
Return on Equity-63.57%
Return on Assets44.05%
Miscellaneous
Employees12
Outstanding Shares101,820,000
Market Cap$1,513.10
Innoviva (NASDAQ:INVA) Frequently Asked Questions
What is Innoviva's stock symbol?
Innoviva trades on the NASDAQ under the ticker symbol "INVA."
How were Innoviva's earnings last quarter?
Innoviva Inc (NASDAQ:INVA) announced its earnings results on Thursday, April, 26th. The biotechnology company reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.50 by $0.23. The biotechnology company earned $52.40 million during the quarter, compared to analyst estimates of $71.84 million. Innoviva had a net margin of 64.11% and a negative return on equity of 63.57%. The company's revenue for the quarter was up 29.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.19 EPS. View Innoviva's Earnings History.
When is Innoviva's next earnings date?
What price target have analysts set for INVA?
6 equities research analysts have issued twelve-month price targets for Innoviva's stock. Their forecasts range from $8.00 to $16.00. On average, they anticipate Innoviva's share price to reach $13.20 in the next year. This suggests that the stock has a possible downside of 6.4%. View Analyst Ratings for Innoviva.
What is the consensus analysts' recommendation for Innoviva?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
Who are some of Innoviva's key competitors?
Some companies that are related to Innoviva include Catalent (CTLT), Ionis Pharmaceuticals (IONS), United Therapeutics (UTHR), FibroGen (FGEN), Loxo Oncology (LOXO), GALAPAGOS NV/S (GLPG), Agios Pharmaceuticals (AGIO), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals (GWPH), Madrigal Pharmaceuticals (MDGL) and Array Biopharma (ARRY).
Who are Innoviva's key executives?
Innoviva's management team includes the folowing people:
- Mr. Eric d'Esparbes, Interim Principal Exec. Officer, Sr. VP & CFO (Age 50)
- Dr. Theodore J. Witek Jr., Sr. VP & Chief Scientific Officer (Age 60)
- Mr. George B. Abercrombie M.B.A., R.Ph., RPh, MBA, Sr. VP & Chief Commercial Officer (Age 63)
- Mr. Geoffrey Hulme, Interim Principal Exec. Officer
- Mr. Jeffrey A. Hagenah Ph.D., Chief Patent Counsel and VP
Has Innoviva been receiving favorable news coverage?
Media headlines about INVA stock have been trending somewhat positive recently, Accern reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Innoviva earned a media sentiment score of 0.20 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 46.36 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Innoviva's major shareholders?
Innoviva's stock is owned by a number of of retail and institutional investors. Top institutional investors include Campbell & CO Investment Adviser LLC (0.04%) and Fox Run Management L.L.C. (0.02%). Company insiders that own Innoviva stock include Eric Desparbes, George B Abercrombie, Michael W Aguiar, Theodore J Jr Witek and Theodore L Witek Jr. View Institutional Ownership Trends for Innoviva.
Which institutional investors are selling Innoviva stock?
INVA stock was sold by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C.. Company insiders that have sold Innoviva company stock in the last year include Eric Desparbes, George B Abercrombie and Michael W Aguiar. View Insider Buying and Selling for Innoviva.
Which institutional investors are buying Innoviva stock?
How do I buy shares of Innoviva?
Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Innoviva's stock price today?
One share of INVA stock can currently be purchased for approximately $14.11.
How big of a company is Innoviva?
Innoviva has a market capitalization of $1.51 billion and generates $217.22 million in revenue each year. The biotechnology company earns $134.14 million in net income (profit) each year or $1.17 on an earnings per share basis. Innoviva employs 12 workers across the globe.
How can I contact Innoviva?
Innoviva's mailing address is 2000 SIERRA POINT PARKWAY SUITE 500, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]
MarketBeat Community Rating for Innoviva (NASDAQ INVA)
MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote "Outperform" if you believe INVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
